Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05329935 · ClinicalTrials.gov registry record

Congenital Athymia Patient Registry

A clinical trial of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome, sponsored by Sumitomo Pharma Switzerland.

Recruiting
Registry status
75
Enrollment target
1
Study location

NCT05329935 is a study of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome that is actively recruiting participants, run by Sumitomo Pharma Switzerland. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05329935, a study of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome, is actively recruiting participants, sponsored by Sumitomo Pharma Switzerland.

RECRUITING
Registry status
75 participants
Enrollment target
1
Study location

Study Summary

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

Interventions

  • BIOLOGICAL Cultured Thymus Tissue

Study Locations (1)

North Carolina

  • Duke University School of Medicine - Durham

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2022-05-25
Est. Completion 2026-04

Sponsor

Sumitomo Pharma Switzerland

13 total trials

What the Registry Record Tells You About NCT05329935

The ClinicalTrials.gov registry entry for NCT05329935 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Complete DiGeorge Anomaly appearing as the primary indexed condition, and to 1 intervention - of which Cultured Thymus Tissue is the first listed.

NCT05329935 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05329935 about?

NCT05329935 is a clinical study titled "Congenital Athymia Patient Registry". This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution ...

What is the current status of trial NCT05329935?

This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2022-05-25. Estimated completion is 2026-04.

What conditions does trial NCT05329935 study?

This clinical trial studies the following conditions: Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, Congenital Athymia.

What interventions are being tested in trial NCT05329935?

The interventions under investigation include: Cultured Thymus Tissue (BIOLOGICAL).

Who is sponsoring clinical trial NCT05329935?

This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05329935 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Complete DiGeorge Anomaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.